Improving personalized treatment planning for targeted radionuclide therapy in cancer patients
Bringing Capacity for Theranostic Dosimetry Planning to the Nuclear Medicine Clinic
['FUNDING_R01'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10829837
This study is working on a new way to make cancer treatment with targeted radiation more effective and safer by using special imaging to tailor the radiation dose for each patient, helping to better treat tumors while protecting healthy organs.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10829837 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of targeted radionuclide therapy (TRT) for cancer treatment by developing a personalized dosimetry planning platform. It aims to use imaging techniques to predict the radiation doses that will be delivered to tumors while minimizing toxicity to healthy organs. By creating a practical and validated system for individualized treatment planning, the research seeks to improve patient outcomes and survival rates. The approach involves integrating advanced imaging tools and protocols to streamline the dosimetry process in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being considered for targeted radionuclide therapy.
Not a fit: Patients who are not eligible for targeted radionuclide therapy or those with conditions that do not respond to this treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments, improving survival rates and reducing side effects for patients undergoing TRT.
How similar studies have performed: Previous research has shown promising results in using personalized dosimetry approaches in radiation therapy, indicating potential success for this novel application in TRT.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DEWARAJA, YUNI K — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: DEWARAJA, YUNI K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers